Recommended dose: 5 mg no more than once per night. Max: 10 mg. Co-administration w/ weak CYP3A inhibitors; moderate hepatic impairment 5 mg no more than once per night.
Discontinue use if patient experiences complex sleep behavior. Worsening of depression & suicidal thoughts & actions (including completed suicides); insomnia or emergence of new cognitive or behavioral abnormalities. Increased risk of CNS depression w/ other CNS depressants (eg, benzodiazepines, opioids, TCAs, alcohol). Patients w/ compromised resp function, moderate to severe obstructive sleep apnea or COPD. Symptoms similar to mild cataplexy may occur. Not to consume alcohol during treatment. Avoid concomitant use w/ strong or moderate CYP3A inhibitors/inducers. May impair ability to drive & other activities requiring complete mental alertness. Not recommended in patients w/ severe hepatic impairment. Increased risk of somnolence in patients w/ severe renal impairment. Pregnancy & lactation. Monitor infants exposed to treatment through breastmilk for excessive sedation. Childn. Exercise caution in elderly ≥65 yr when using doses >5 mg.
Sign Out
